BASKING RIDGE, N.J., Dec. 12, 2017 /PRNewswire/ — Daiichi Sankyo, Inc., (hereafter, Daiichi Sankyo), today announced results from the Hokusai-VTE CANCER study evaluating oral edoxaban (known by the brand names SAVAYSA® in the U.S. and LIXIANA® outside the U.S.), and found that edoxaban…